ISIS Pharmaceuticals, Inc.  

(Public, NASDAQ:ISIS)   Watch this stock  
Find more results for ISIS
0.00 (0.00%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 37.38 - 77.80
Open     -
Vol / Avg. 0.00/1.87M
Mkt cap 7.50B
P/E 561.93
Div/yield     -
EPS 0.11
Shares 120.12M
Beta 1.76
Inst. own 89%
Dec 1, 2015
Isis Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - 1:30PM EST - Add to calendar
Nov 18, 2015
Isis Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 11, 2015
Isis Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 9, 2015
Q3 2015 Isis Pharmaceuticals Inc Earnings Call
Nov 9, 2015
Q3 2015 Isis Pharmaceuticals Inc Earnings Release
Nov 8, 2015
Isis Pharmaceuticals' Webcast to Review ISIS-APO(a) Rx and ISIS-APO(a)-L Rx Data Presented at AHA Conference Call - Webcast
Nov 3, 2015
Isis Pharmaceuticals Inc to Review ISIS-TTRRx Data Presented at 1st European Congress of Hereditary ATTR Amyloidosis and Provide Phase 3 Development Plan Update Conference Call - Webcast
Sep 30, 2015
Leerink Partners Rare Disease Roundtable
Sep 18, 2015
Isis Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
Sep 10, 2015
Isis Pharmaceuticals Inc at Wells Fargo Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -72.83% -18.20%
Operating margin -98.00% -26.16%
EBITD margin - -17.90%
Return on average assets -14.61% -4.32%
Return on average equity -52.59% -12.26%
Employees 390 -
CDP Score - -


2855 Gazelle Ct
CARLSBAD, CA 92010-6670
United States - Map
+1-760-9319200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Isis Pharmaceuticals, Inc. (Isis) is a Ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is focused to discover and develop antisense drugs. The antisense drugs are used to treat a range of diseases, including cardiovascular, metabolic, severe and rare diseases, including neurological disorders and cancer. ISIS-APOCIII is a drug indicated to to treat patients with high triglyceride levels, including patients with a genetic condition called familial chylomicronemia syndrome (FCS) and patients with partial lipodystrophy. In addition to ISIS-APOCIII, it is also evaluating ISIS-TTR and ISIS-SMN in Phase III studies. Its lipid-lowering product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia (HoFH).

Officers and directors

Stanley T. Crooke M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Elizabeth L. Hougen Chief Financial Officer, Senior Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Chief Operating Officer, Corporate Secretary, Director
Age: 61
Bio & Compensation  - Reuters
Patrick R. O'Neil Esq. Senior Vice President - Legal, General Counsel
Age: 41
Bio & Compensation  - Reuters
C. Frank Bennett Ph.D. Senior Vice President - Antisense Research
Age: 58
Bio & Compensation  - Reuters
Richard S. Geary Ph.D. Senior Vice President - Development
Age: 57
Bio & Compensation  - Reuters
Brett P. Monia Ph.D. Senior Vice President - Drug Discovery and Corporate Development
Age: 53
Bio & Compensation  - Reuters
Sarah Boyce Chief Business Officer
Age: 43
Bio & Compensation  - Reuters
Joseph Loscalzo M.D., Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Spencer R. Berthelsen M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters